AbbVie Reports Promising Results from Phase 1 Study of ABBV-295

AbbVie Inc. (NYSE:ABBV) is included among the 13 Undervalued Dividend Aristocrats to Buy Now.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

On March 9, AbbVie Inc. (NYSE:ABBV) reported encouraging results from a phase 1 study of its ABBV-295 drug, a long-acting amylin analog for treating obesity. The study led to significant weight loss at weekly, bi-weekly, and monthly dosing schedules among adult candidates.

The average weight loss ranged from -7.75% to -9.79% at week 12 with weekly dosing. Meanwhile, the weight loss averaged between -7.86% to -9.73% at week 13 with every other week dosing, followed by monthly dosing after week five. Notably, the drug was generally well tolerated across all dose levels, with the most common side effects being gastrointestinal in nature and mild.

Primal Kaur, M.D., senior vice president, global development of immunology, neuroscience, eye care, and specialty at AbbVie Inc. (NYSE:ABBV), commented:

“Obesity is a complex, chronic disease that places a substantial burden on patients, healthcare systems and society, and there remains a critical need for therapies that combine efficacy with tolerability and support long-term adherence. We are encouraged by these early results for ABBV-295, which demonstrate meaningful weight loss together with a well-tolerated safety profile. These initial results further reinforce the potential of ABBV-295 as a novel therapeutic option for people living with obesity.”

With a P/E ratio of 15.82 as of the writing of this piece, AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Undervalued Stocks to Invest in Right Now.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading into 2026 and 11 Best Utility Stocks to Buy for Dividends in 2026.

Disclosure: None. Follow Insider Monkey on Google News.